These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 24108668)

  • 21. Phase II study of capecitabine and the oral mTOR inhibitor everolimus in patients with advanced pancreatic cancer.
    Kordes S; Klümpen HJ; Weterman MJ; Schellens JH; Richel DJ; Wilmink JW
    Cancer Chemother Pharmacol; 2015 Jun; 75(6):1135-41. PubMed ID: 25822310
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Phase I study of everolimus, cetuximab and irinotecan as second-line therapy in metastatic colorectal cancer.
    Hecht JR; Reid TR; Garrett CR; Beck JT; Davidson SJ; Mackenzie MJ; Brandt U; Rizvi S; Sharma S
    Anticancer Res; 2015 Mar; 35(3):1567-73. PubMed ID: 25750312
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Phase I trial of oral mTOR inhibitor everolimus in combination with trastuzumab and vinorelbine in pre-treated patients with HER2-overexpressing metastatic breast cancer.
    Jerusalem G; Fasolo A; Dieras V; Cardoso F; Bergh J; Vittori L; Zhang Y; Massacesi C; Sahmoud T; Gianni L
    Breast Cancer Res Treat; 2011 Jan; 125(2):447-55. PubMed ID: 21107682
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Phase I study of bevacizumab, everolimus, and panobinostat (LBH-589) in advanced solid tumors.
    Strickler JH; Starodub AN; Jia J; Meadows KL; Nixon AB; Dellinger A; Morse MA; Uronis HE; Marcom PK; Zafar SY; Haley ST; Hurwitz HI
    Cancer Chemother Pharmacol; 2012 Aug; 70(2):251-8. PubMed ID: 22744359
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A phase I study of the VEGFR kinase inhibitor vatalanib in combination with the mTOR inhibitor, everolimus, in patients with advanced solid tumors.
    Zhu M; Molina JR; Dy GK; Croghan GA; Qi Y; Glockner J; Hanson LJ; Roos MM; Tan AD; Adjei AA
    Invest New Drugs; 2020 Dec; 38(6):1755-1762. PubMed ID: 32328844
    [TBL] [Abstract][Full Text] [Related]  

  • 26. 18F-FLT PET as a surrogate marker of drug efficacy during mTOR inhibition by everolimus in a preclinical cisplatin-resistant ovarian tumor model.
    Aide N; Kinross K; Cullinane C; Roselt P; Waldeck K; Neels O; Dorow D; McArthur G; Hicks RJ
    J Nucl Med; 2010 Oct; 51(10):1559-64. PubMed ID: 20847160
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A Phase I Trial of the IGF-1R Antibody Ganitumab (AMG 479) in Combination with Everolimus (RAD001) and Panitumumab in Patients with Advanced Cancer.
    Vlahovic G; Meadows KL; Hatch AJ; Jia J; Nixon AB; Uronis HE; Morse MA; Selim MA; Crawford J; Riedel RF; Zafar SY; Howard LA; O'Neill M; Meadows JJ; Haley ST; Arrowood CC; Rushing C; Pang H; Hurwitz HI
    Oncologist; 2018 Jul; 23(7):782-790. PubMed ID: 29572245
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Open-label randomized clinical trial of standard neoadjuvant chemotherapy with paclitaxel followed by FEC versus the combination of paclitaxel and everolimus followed by FEC in women with triple receptor-negative breast cancer†.
    Gonzalez-Angulo AM; Akcakanat A; Liu S; Green MC; Murray JL; Chen H; Palla SL; Koenig KB; Brewster AM; Valero V; Ibrahim NK; Moulder-Thompson S; Litton JK; Tarco E; Moore J; Flores P; Crawford D; Dryden MJ; Symmans WF; Sahin A; Giordano SH; Pusztai L; Do KA; Mills GB; Hortobagyi GN; Meric-Bernstam F
    Ann Oncol; 2014 Jun; 25(6):1122-7. PubMed ID: 24669015
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Feasibility of adding everolimus to carboplatin and paclitaxel, with or without bevacizumab, for treatment-naive, advanced non-small cell lung cancer.
    Eberhardt WE; Mitchell P; Schiller JH; Brown MP; Thomas M; Mills G; Jehl V; Urva SR; De Leo JJ; Gogov S; Papadimitrakopoulou V
    Invest New Drugs; 2014 Feb; 32(1):123-34. PubMed ID: 23579358
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A phase Ib study investigating the combination of everolimus and dovitinib in vascular endothelial growth factor refractory clear cell renal cancer.
    Powles T; Foreshew SJ; Shamash J; Sarwar N; Crabb S; Sahdev A; Nixon J; Lim L; Pungaliya A; Foreshaw A; Davies R; Greenwood M; Wilson P; Pacey S; Galazi M; Jones R; Chowdhury S
    Eur J Cancer; 2014 Aug; 50(12):2057-64. PubMed ID: 24908540
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Sorafenib and everolimus in patients with advanced solid tumors and KRAS-mutated NSCLC: A phase I trial with early pharmacodynamic FDG-PET assessment.
    Nogova L; Mattonet C; Scheffler M; Taubert M; Gardizi M; Sos ML; Michels S; Fischer RN; Limburg M; Abdulla DSY; Persigehl T; Kobe C; Merkelbach-Bruse S; Franklin J; Backes H; Schnell R; Behringer D; Kaminsky B; Eichstaedt M; Stelzer C; Kinzig M; Sörgel F; Tian Y; Junge L; Suleiman AA; Frechen S; Rokitta D; Ouyang D; Fuhr U; Buettner R; Wolf J
    Cancer Med; 2020 Jul; 9(14):4991-5007. PubMed ID: 32436621
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Phase I study of capecitabine, oxaliplatin, bevacizumab, and everolimus in advanced solid tumors.
    Rangwala F; Bendell JC; Kozloff MF; Arrowood CC; Dellinger A; Meadows J; Tourt-Uhlig S; Murphy J; Meadows KL; Starr A; Broderick S; Brady JC; Cushman SM; Morse MA; Uronis HE; Hsu SD; Zafar SY; Wallace J; Starodub AN; Strickler JH; Pang H; Nixon AB; Hurwitz HI
    Invest New Drugs; 2014 Aug; 32(4):700-9. PubMed ID: 24711126
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phase I trial of cixutumumab combined with temsirolimus in patients with advanced cancer.
    Naing A; Kurzrock R; Burger A; Gupta S; Lei X; Busaidy N; Hong D; Chen HX; Doyle LA; Heilbrun LK; Rohren E; Ng C; Chandhasin C; LoRusso P
    Clin Cancer Res; 2011 Sep; 17(18):6052-60. PubMed ID: 21750201
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A phase II study of bevacizumab and everolimus as treatment for refractory metastatic renal cell carcinoma.
    Harshman LC; Barbeau S; McMillian A; Srinivas S
    Clin Genitourin Cancer; 2013 Jun; 11(2):100-6. PubMed ID: 23352238
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phase I study investigating everolimus combined with sorafenib in patients with advanced hepatocellular carcinoma.
    Finn RS; Poon RT; Yau T; Klümpen HJ; Chen LT; Kang YK; Kim TY; Gomez-Martin C; Rodriguez-Lope C; Kunz T; Paquet T; Brandt U; Sellami D; Bruix J
    J Hepatol; 2013 Dec; 59(6):1271-7. PubMed ID: 23928403
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A phase 1 study of everolimus plus docetaxel plus cisplatin as induction chemotherapy for patients with locally and/or regionally advanced head and neck cancer.
    Fury MG; Sherman E; Ho AL; Xiao H; Tsai F; Nwankwo O; Sima C; Heguy A; Katabi N; Haque S; Pfister DG
    Cancer; 2013 May; 119(10):1823-31. PubMed ID: 23408298
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dual inhibition of the epidermal growth factor receptor pathway with cetuximab and erlotinib: a phase I study in patients with advanced solid malignancies.
    Guarino MJ; Schneider CJ; Hosford MA; Brahmer JR; Rudin CM; Finckenstein FG; Philip-Norton RE; Lu H; Weber MR; Ettinger DS
    Oncologist; 2009 Feb; 14(2):119-24. PubMed ID: 19182243
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A phase 1 study of everolimus + weekly cisplatin + intensity modulated radiation therapy in head-and-neck cancer.
    Fury MG; Lee NY; Sherman E; Ho AL; Rao S; Heguy A; Shen R; Korte S; Lisa D; Ganly I; Patel S; Wong RJ; Shaha A; Shah J; Haque S; Katabi N; Pfister DG
    Int J Radiat Oncol Biol Phys; 2013 Nov; 87(3):479-86. PubMed ID: 24074921
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A phase Ib trial of LY2584702 tosylate, a p70 S6 inhibitor, in combination with erlotinib or everolimus in patients with solid tumours.
    Hollebecque A; Houédé N; Cohen EE; Massard C; Italiano A; Westwood P; Bumgardner W; Miller J; Brail LH; Benhadji KA; Soria JC
    Eur J Cancer; 2014 Mar; 50(5):876-84. PubMed ID: 24456794
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phase I study and preclinical efficacy evaluation of the mTOR inhibitor sirolimus plus gemcitabine in patients with advanced solid tumours.
    Martin-Liberal J; Gil-Martín M; Sáinz-Jaspeado M; Gonzalo N; Rigo R; Colom H; Muñoz C; Tirado OM; García del Muro X
    Br J Cancer; 2014 Aug; 111(5):858-65. PubMed ID: 25003665
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.